The JAK/STAT signaling pathway is a critical regulator of cellular processes, including immune responses, inflammation, and cell growth. It was first discovered in the 1990s through studies on interferon (IFN) signaling. The pathway involves Janus kinases (JAKs) and signal transducers and activators of transcription (STATs), which transmit signals from cell surface receptors to the nucleus, where they regulate gene expression. JAKs are non-receptor tyrosine kinases that phosphorylate receptors and recruit STAT proteins, which then dimerize and translocate to the nucleus to activate target genes. STATs are involved in various biological functions, including immune regulation, cell differentiation, and apoptosis. Dysregulation of the JAK/STAT pathway is associated with numerous diseases, including cancers and autoimmune disorders. The JAK/STAT pathway is composed of four JAK family members (JAK1, JAK2, JAK3, and TYK2) and seven STAT family members (STAT1-6). Each JAK and STAT has specific roles in signal transduction, with JAKs phosphorylating STATs and STATs regulating gene expression. The pathway is activated by various cytokines and growth factors, and its regulation involves both positive and negative mechanisms. Positive regulation includes the activation of JAKs and STATs by cytokine receptors, while negative regulation involves proteins such as SOCS, PIAS, and PTPs that inhibit JAK/STAT signaling to prevent excessive activation. The JAK/STAT pathway interacts with other signaling pathways, such as the TGFβ, MAPK, Notch, and PI3K/AKT/mTOR pathways, which are involved in cell proliferation, differentiation, and survival. These interactions are crucial for maintaining cellular homeostasis and preventing disease. Inhibitors of the JAK/STAT pathway, such as JAK inhibitors, are being developed for the treatment of various diseases, including cancers and autoimmune disorders. The pathway's role in disease and its potential as a therapeutic target make it an important area of research in both basic science and clinical medicine.The JAK/STAT signaling pathway is a critical regulator of cellular processes, including immune responses, inflammation, and cell growth. It was first discovered in the 1990s through studies on interferon (IFN) signaling. The pathway involves Janus kinases (JAKs) and signal transducers and activators of transcription (STATs), which transmit signals from cell surface receptors to the nucleus, where they regulate gene expression. JAKs are non-receptor tyrosine kinases that phosphorylate receptors and recruit STAT proteins, which then dimerize and translocate to the nucleus to activate target genes. STATs are involved in various biological functions, including immune regulation, cell differentiation, and apoptosis. Dysregulation of the JAK/STAT pathway is associated with numerous diseases, including cancers and autoimmune disorders. The JAK/STAT pathway is composed of four JAK family members (JAK1, JAK2, JAK3, and TYK2) and seven STAT family members (STAT1-6). Each JAK and STAT has specific roles in signal transduction, with JAKs phosphorylating STATs and STATs regulating gene expression. The pathway is activated by various cytokines and growth factors, and its regulation involves both positive and negative mechanisms. Positive regulation includes the activation of JAKs and STATs by cytokine receptors, while negative regulation involves proteins such as SOCS, PIAS, and PTPs that inhibit JAK/STAT signaling to prevent excessive activation. The JAK/STAT pathway interacts with other signaling pathways, such as the TGFβ, MAPK, Notch, and PI3K/AKT/mTOR pathways, which are involved in cell proliferation, differentiation, and survival. These interactions are crucial for maintaining cellular homeostasis and preventing disease. Inhibitors of the JAK/STAT pathway, such as JAK inhibitors, are being developed for the treatment of various diseases, including cancers and autoimmune disorders. The pathway's role in disease and its potential as a therapeutic target make it an important area of research in both basic science and clinical medicine.